Table 3.
Prevalence of MetS by definition
| Author and publication year | HIV status | Prevalence by definition criteria | ||||
|---|---|---|---|---|---|---|
| HIV+ | HIV− | IDF | ATP | Others | ||
| 1 | Amusa et al., 2016 [33] | 150 | 50 | NA | NA | 41 (27.3%), P < 0.01Ϯ 2 (4%), P < 0.01α—not stated |
| 2 | Ayodele et al., 2012 [32] | 291 | NA | 50 (17.2%) | 37 (12.7%) | 61(21.0%)—JIS |
| 3 | Berhane et al., 2012 [34] | 313 | NA | NA | 66 (21.1%) | NA |
| 4 | Tesfaye et al., 2014 [42] | 374 | NA | 23.8% | 16.8% | NA |
| 5 | Sobieszczyk et al., 2016 [29] | 160 | NA | NA | 27 (8.7%) | NA |
| 6 | Obirikorang et al., 2016 [41] | 433 | NA | 183 (42.3%) | 209 (48.3%) | 106 (24.5%)—WHO |
| 7 | Ngatchou et al., 2013 [40] | 108 | 96 | 47.0%, P = 0.02Ϯ 21.0%, P = 0.02α |
NA | NA |
| 8 | Fourie et al., 2010 [35] | 300 | 300 | 21.1%, P = 0.65Ϯ 22.6%, P = 0.65α |
15.2% P = 0.18Ϯ 11.5% P = 0.18α |
NA |
| 9 | Muhammad et al., 2013 [45] | 200 | NA | ART = 21.0%; Naive = 9.0% P = 0.017 |
NA | NA |
| 10 | Mbunkah et al., 2014 [38] | 173 | 50 | NA | 15.6% (27/173) (P = 0.020)Ϯ 8.0% (4/50)α |
NA |
| 11 | Guehi et al., 2016 [30] | 755 | NA | NA | 47 (6.2%) P > 0.0001 | NA |
| 12 | Mashinya et al., 2015 [37] | 214 | NA | NA | 20 (9.6%) P = 0.56 | NA |
| 13 | Guira et al., 2016 [31] | 300 | NA | 54 (18.0%) | NA | NA |
| 14 | Hirigo et al., 2016 [36] | 185 | NA | 24.3% (45/185) | 17.8% | NA |
| 15 | Zannou et al., 2009 [28] | 79 | NA | 10 (12.7%) | NA | NA |
| 16 | Muyanja et al., 2016 [39] | 250 | NA | NA | 145/250 (58.0%) P value = 0.10 | NA |
,NA not applicable
αHIV-negative
ϮHIV-positive